Quantcast

Altogen Labs Offers New Pre-Clinical CRO Services to Accelerate Pre-Clinical Research Needs

April 26, 2013

Altogen Labs is a GLP compliant laboratory that provides preclinical research and biology contract research services (CRO). Altogen Labs now offers wide variety of preclinical CRO services, including drug development, generation of stable cell lines, RNAi gene silencing and in vivo research services (xenograft, in vivo siRNA delivery), pharm/tox assays (IC50), cell banking, and ELISA assay development.

Austin, TX (PRWEB) April 26, 2013

Altogen Labs, a biotechnology company focused on providing biotechnology research services for pharmaceutical, biotechnology, and academic institutions worldwide, today announced addition of new pre-clinical contract research services enabling companies to accelerate pre-clinical research needs.

Pre-clinical trials assess the toxicity and pharmacological activity of investigative new drugs (INDs) to assess a compound´s therapeutic potential and safety for human use. A very important component of pre-clinical trials includes in vivo toxicology analysis. At Altogen Labs, in vivo toxicology studies can include acute, subchronic, and chronic toxicity tests to study of toxic effects of chemical substances.

Altogen Labs provides following in vivo services for efficacy studies in the drug discovery phase: rodent xenograft models, teratoma formation and analysis services, cancer disease animal models, in vivo siRNA delivery and tissue targeting, pharmacokinetics (PK) and pharmacodynamics (PD) services, immune response and biomarker analysis.

To accelerate the development of new anti-cancer medicines, Altogen Labs offers in vivo xenograft services for drug development studies to treat inflammation, infectious diseases, cancer, pain, immunology and obesity. As a GLP-compliant laboratory, animal handling is IACUC-regulated and in accordance with FDA regulations. A variety of disease models are now available for testing.

Altogen Labs excels in providing excellent preservation and maintenance of cell banks. Cell viability is ensured by our redundant backup system in our secure, monitored and controlled storage facility. Cell banking services include maintenance and around the clock monitoring of cell bank environments, providing clients with cell lines free of bacterial and mycoplasma contamination.

Altogen Labs, also provides generation of stable cell line services from start to finish. The development of stable cell lines is a necessity to science today and provides researchers with the ability to design, create, and characterize stable cell lines that express a gene of interest. Although this process is time consuming, at Altogen Labs the generation of stable cell lines can take as little as 6-12 weeks.

By offering RNA Interference (RNAi) services, Altogen Labs provide clients with RNAi gene silencing in vivo and in vitro services from beginning to end. These RNAi services include the design and development of in vivo stable siRNA, shRNA, and microRNA, tissue targeting and stable RNAi knockdown cell line development, siRNA library screening, RNAi delivery, development of in vivo siRNA transfection reagents and kits, qPCR quantification of mRNA knockdown or amplification effects, in vitro functional testing, and gene targeting.

About Altogen Labs

Altogen Labs is a contract research organization (CRO) providing biotechnology research services for pharmaceutical, biotechnology, and academic institutions worldwide. Altogen Labs services include skilled laboratory CRO pre-clinical research, including generation of stable cell lines and tissue culture compound testing services, in vivo toxicology studies for IND applications, biodistribution studies and xenograft animal models, gene expression analysis, as well as tissue-targeted in vivo RNAi and siRNA delivery services. Altogen Labs is headquartered in Austin, TX. For more information, please visit AltogenLabs.com, e-mail info(at)altogenlabs(dot)com, or call us 512-433-6177.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10674479.htm


Source: prweb



comments powered by Disqus